Amar Kishan, Radiation Oncologist, Professor, and Executive Vice Chair of Radiation Oncology at UCLA, shared a post by JAMA Oncology on X about recent paper he and his colleagues authored, adding:
“Proud to share 2-year patient-reported outcomes for our phase II SCIMITAR trial (NCT03541850) of SBRT to the prostate fossa (with or without nodes), out today in JAMA Oncology.
We were fortunate to have a strong collaborative team UCLA Jonsson Comprehensive Cancer Center including UCLA Urology, as well as a comparator cohort of patients receiving conventionally fractionated IMRT at UChicago Medicine, Stan Liauw and Connor Lynch.
Special kudos to soon-to-be U Penn attending, John Nikitas, who has now pulled off first author papers in JAMA Onc, Lancet Onc, European Urology, Red Journal, and Green Journal in residency!
And thanks to many collaborators including Leslie Ballas, and, most importantly, the patients who enrolled in this trial. Oncologic outcomes (primary endpoint) to be reported at ASTRO 2025.
Editorial by Sean McBride and Howard Scher.”
Quoting JAMA Oncology‘s post:
“Postoperative stereotactic body radiotherapy for prostate cancer was well-tolerated with similar urinary and bowel patient-reported outcomes over two years vs conventional radiotherapy.”
Journal: JAMA Oncology
Authors: John Nikitas, Leslie K. Ballas, Tahmineh Romero, Connor Lynch, Ting Martin Ma, Luca F. Valle, Ankush Sachdeva, Natalie Chong, Vince Basehart, Antonio Franco, Robert Reiter, Christopher Saigal, Karim Chamie, Mark S. Litwin, Nicholas M. Donin, Matthew Rettig, Nicholas G. Nickols, Minsong Cao, Stanley L. Liauw, Michael L. Steinberg, Amar U. Kishan
